Rapport Therapeutics Files 8-K

Ticker: RAPP · Form: 8-K · Filed: Sep 8, 2025 · CIK: 2012593

Rapport Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyRapport Therapeutics, Inc. (RAPP)
Form Type8-K
Filed DateSep 8, 2025
Risk Levellow
Pages6
Reading Time7 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

Rapport Therapeutics filed an 8-K, standard procedure but always worth checking for news.

AI Summary

On September 8, 2025, Rapport Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This filing indicates Rapport Therapeutics is making a regulatory disclosure and reporting on other events and financial statements, which is standard for public companies but may contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification without specific material events or financial disclosures that would indicate immediate risk.

Key Players & Entities

  • Rapport Therapeutics, Inc. (company) — Registrant
  • 001-42121 (company) — SEC File Number
  • 88-0724208 (company) — IRS Employer Identification No.
  • 02210 (dollar_amount) — ZIP Code

FAQ

What is the primary purpose of this 8-K filing for Rapport Therapeutics, Inc.?

The filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported is dated September 8, 2025.

What is Rapport Therapeutics, Inc.'s state of incorporation?

Rapport Therapeutics, Inc. is incorporated in Delaware.

What is the principal executive office address for Rapport Therapeutics, Inc.?

The principal executive offices are located at 99 High Street, Suite 2100, Boston, Massachusetts, 02210.

What is the SIC code for Rapport Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Rapport Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,828 words · 7 min read · ~6 pages · Grade level 12 · Accepted 2025-09-08 06:12:16

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value per share RAPP The Nasdaq

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will" and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of RAP-219 for the treatment of focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain, including the initiation, timing, progress and results of the Company's Phase 3 clinical trials in focal onset seizures, and a Phase 2 clinical trial of RAP-219 in bipolar mania, as well as other planned clinical trials; expectations for the activity, tolerability, and commercial potential of RAP-219; the future release of data from the ongoing 8-week follow-up period of the Phase 2a trial for RAP-219; expectations for a LAI formulation of RAP-219 and the potential of a LAI to improve patient adherence; the Company's expectations for upcoming regulatory interactions; the potential of Rapport's RAP technology platform; and expectations for Rapport's uses of capital, expenses and financial results. Forward looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect Rapport's business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company's research and development activities; Rapport's ability to execute on its strategy including obtaining the requisite regulatory

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Rapport Therapeutics, Inc. on September 8, 2025, furnished herewith. 99.2 Corporate presentation of Rapport Therapeutics, Inc., furnished herewith. 104 Cover Page Interactive Data File (embedded within Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rapport Therapeutics, Inc. Date: September 8, 2025 By: /s/ Troy Ignelzi Troy Ignelzi Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.